WS Investor
30 Jan 2026, 09:19
BioMarin Pharmaceutical Inc. announced the pricing of a major debt financing package to support its pending acquisition of Amicus Therapeutics.
The company priced an $850 million private offering of 5.500% senior unsecured notes due 2034, issued at par, with closing expected on February 12, 2026. In parallel, BioMarin completed the syndication of a new $2 billion senior secured Term Loan B facility, in addition to an existing $800 million Term Loan A facility and a planned $600 million senior secured revolving credit facility.
BioMarin plans to use the proceeds from the notes, term loans, and cash on hand to fund the Amicus acquisition and related transaction costs. The notes will be placed into escrow and are subject to mandatory redemption if the acquisition is not completed by December 19, 2026. The debt will be guaranteed by certain BioMarin subsidiaries, including Amicus following the transaction, and will include customary restrictive covenants.
Source: PRNewswire
The company priced an $850 million private offering of 5.500% senior unsecured notes due 2034, issued at par, with closing expected on February 12, 2026. In parallel, BioMarin completed the syndication of a new $2 billion senior secured Term Loan B facility, in addition to an existing $800 million Term Loan A facility and a planned $600 million senior secured revolving credit facility.
BioMarin plans to use the proceeds from the notes, term loans, and cash on hand to fund the Amicus acquisition and related transaction costs. The notes will be placed into escrow and are subject to mandatory redemption if the acquisition is not completed by December 19, 2026. The debt will be guaranteed by certain BioMarin subsidiaries, including Amicus following the transaction, and will include customary restrictive covenants.
Source: PRNewswire